Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29719222 | 1.00 | EGFR (0.51) | EGFRGAKEPHA2KDREPHB4 | |
| SCHEMBL29719043 | 0.86 | EGFR (0.56) | EGFRGAKEPHA2KDREPHB4 | |
| SCHEMBL22983497 | 0.86 | EGFR (0.56) | EGFRGAKEPHA2KDREPHB4 | |
| SCHEMBL22983689 | 0.86 | EGFR (0.64) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL22983908 | 0.85 | EGFR (0.52) | EGFRGAKEPHA2KDREPHB4 | |
| SCHEMBL29718888 | 0.85 | EGFR (0.52) | EGFRGAKEPHA2KDREPHB4 | |
| SCHEMBL21835197 | 0.84 | EGFR (0.56) | EGFRERBB2ERBB4 | |
| SCHEMBL29718910 | 0.84 | EGFR (0.56) | EGFRERBB2ERBB4 | |
| SCHEMBL21835520 | 0.80 | EGFR (0.56) | EGFRKDRERBB2ERBB4 | |
| SCHEMBL2533768 | 0.79 | EGFR (0.79) | EGFRGAKERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013749-B1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114787150-A | Alkynyl quinazoline compounds | 黑钻治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4013749-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | Black Diamond Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | EGFR 677/4885GAK 612/4885EPHA2 3616/4885 |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | GLS, GLS2, MCL1 | EGFR 677/4885GAK 612/4885EPHA2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.